Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Vistagen Therapeutics

03/08/2026 23:19

Vistagen Therapeutics Inc VTGN.OQ VTGN.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The South San Francisco California-based  company is expected to report a 2.5% increase in revenue to $250 thousand from $244 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Vistagen Therapeutics Inc is for a loss of 36 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $1.00, about 308.2% above its last closing price of $0.25
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.34
-0.37
Missed
-9.9
Dec. 31 2026
-0.50
-0.49
-0.45
Beat
7.4
Sep. 30 2025
-0.47
-0.48
-0.54
Missed
-13.4​
Jun. 30 2025
-0.48
-0.47
-0.47
Met
0.7
​​Mar. 31 2025
-0.52
-0.50
-0.43
Beat
13
Dec. 31 2024
-0.51
-0.51
-0.46
Beat
9.8​
Sep. 30 2024
-0.39
-0.39
-0.42
Missed
-7.7
Jun. 30 2024
-0.41
-0.40
-0.35
Beat
13.6
This summary was machine generated August 3 at 22:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)